



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alice A. Martino *et al.*

Serial No.: 10/072,368

Filed: February 7, 2002

For: RAPID-ONSET MEDICAMENT FOR  
TREATMENT OF SEXUAL DYSFUNCTION

Examiner: Unknown

) Attorney Docket:  
) C-3527/1/US

)  
)  
) Group Art Unit:  
) Unknown

PATENT

TECH CENTER 1600/2900

AUG 14 2002

RECEIVED

**Certificate of Mailing**

I, Bernadette Y. Harper hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on August 8, 2002.

Signed:

*Bernadette Y. Harper*

Date:

*8/8/02*

INFORMATION DISCLOSURE STATEMENT, UNDER 37 CFR §1.97(b)

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:


Applicants hereby submit copies of patents, publications or other information of which they are aware that they believe may be material to the examination of this application, and in respect of which there may be a duty to disclose under 37 CFR § 1.56.

A list of all enclosed documents is provided in a PTO Form 1449, transmitted herewith.

This information disclosure statement is being filed within three months of the filing date of the above-cited patent application or prior to the mailing of a first Office action on the merits, in accordance with 37 CFR § 1.97(b). Accordingly, no fee is believed required under 37 CFR § 1.97. However, if any fee is required in connection with this Information Disclosure Statement, please charge account number 19-1025.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR §1.97(g)), an admission that the information cited is or is considered to be, material to patentability, or that no other material information exists.

Dated: August 8, 2002

  
\_\_\_\_\_  
James C. Forbes  
Agent for Applicants  
Reg. No. 39,457



Form PTO-1449  
(Rev. 8-88)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.

Serial No.

C-3527/1/US

10/072,368

Applicant


Alice C. Martino *et al.*

Filing Date

February 7, 2002

Group No.

Unknown



## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

RECEIVED  
 AUG 14 2002  
 TELETYPE CENTER  
 100/2000

## U.S. PATENT DOCUMENTS

Examiner Initial*	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	5,869,098	Feb 09, 1999	Misra <i>et al.</i>	424	484	
	5,876,759	Mar 02, 1999	Gowan, Jr.	424	494	
	5,888,534	Mar 30, 1999	El-Rashidy <i>et al.</i>	424	435	
	5,891,916	Apr 06, 1999	Kato <i>et al.</i>	514	575	
	5,939,091	Aug 17, 1999	Eoga <i>et al.</i>	424	441	
	5,939,094	Aug 17, 1999	Durif <i>et al.</i>	424	448	
	5,945,117	Aug 31, 1999	El-Rashidy, <i>et al.</i>	424	430	
	5,954,204	Sep 21, 1999	Grabowski	206	531	
	5,958,453	Sep 28, 1999	Ohno <i>et al.</i>	424	465	
	5,985,889	Nov 16, 1999	El-Rashidy <i>et al.</i>	514	284	
	5,994,363	Nov 30, 1999	El-Rashidy <i>et al.</i>	514	284	
	6,010,719	Jan 04, 2000	Remon <i>et al.</i>	424	464	
	6,024,981	Feb 15, 2000	Khankari <i>et al.</i>	424	464	
	6,083,527	Jul 04, 2000	Thistle	424	440	
	6,087,362	Jul 11, 1000	El-Rashidy	514	253	
	6,121,276	Sep 19, 2000	El-Rashidy <i>et al.</i>	514	284	
	6,193,992	Feb 27, 2001	El-Rashidy <i>et al.</i>	424	430	
	6,200,983	Mar 13, 2001	El-Rashidy <i>et al.</i>	514	284	
	6,291,471	Sep 18, 2001	Kling <i>et al.</i>	514	284	
	6,306,437	Oct 23, 2001	El-Rashidy <i>et al.</i>	424	464	
	2002/0006933	Jan 17, 2002	Gupta <i>et al.</i>	514	295	

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	EP0940084	Sep 08, 1999	EP	A23G	1/100		
	EP0960621	Dec 12, 1999	EP	A61K	31/505		
	EP0992240	Apr 04, 2000	EP	A61K	31/435		
	EP1145714	Oct 17, 2001	EP	A61K	31/4375		
	WO9916442	Apr 08, 1999	WIPO	A61K	31/47		
	WO9966933	Dec 29, 1999	WIPO	A61K	31/505		
	WO0035457	Jun 22, 2000	WIPO	A61K	31/485		
	WO0040226	Jul 13, 2000	WIPO	A61K	31/00		
	WO0042992	Jul 27, 2000	WIPO	A61K	9/70		
	WO0047203	Aug 17, 2000	WIPO	A61K	31/28		

Examiner

Date Considered

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

Form PTO-1449  
(Rev. 8-88)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.

Serial No.

C-3527/1/US

10/072,380

Applicant

Alice C. Martino *et al.*

Filing Date

February 7, 2002

Group No.

Unknown

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO0076509	Dec 21, 2000	WIPO	A61K	31/44		
	WO0110406	Feb 15, 2001	WIPO	A61K	9/00		
	WO0149292	Jul 12, 1001	WIPO	A61K	31/485		
	WO0176602	Oct 18, 2001	WIPO	A61K	31/473		
	WO0205820	Jan 24, 2002	WIPO	A61K	31/495		

## OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

	<a href="http://www.tomescps.com/hcsdata/de/de1066.htm">http://www.tomescps.com/hcsdata/de/de1066.htm</a> , pp. 1-33. Apomorphine
	Schuh <i>et al.</i> "Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet" <i>Drug and Alcohol Dependence</i> , 56(1), 55-60 (1999).
	Chang <i>et al.</i> "Fast-Dissolving Tablets", <i>Pharmaceutical Technology</i> , pp. 52-58, June (2000).
	Dong Yoo <i>et al.</i> "Increased Bioavailability of Clomipramine after Sublingual Administration in Rats", <i>Journal of Pharmaceutical Sciences</i> 88(11), (1999).
	<i>Diagnostic and Statistical Manual of Mental Disorders</i> , 4 <sup>th</sup> edition (DSM-IV) (1994), and DSM-IV Guidebook (1995), both published by American Psychiatric Press, Inc., Washington, DC
	Gingell <i>et al.</i> "Emerging pharmaceutical therapies for erectile dysfunction", <i>Expert Opinion on Therapeutic Patents</i> 9, 1689-1696 (1999).
	Heier <i>et al.</i> "Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites", <i>J. Med. Chem.</i> 40,639-646, (1997).
	Shephard <i>et al.</i> "Pharmacokinetic behavior of sublingually administered 8-methoxypsoralen for PUVA therapy", <i>Photodermatology, Photoimmunology &amp; Photomedicine</i> 17, 11-21(2001).
	Watson <i>et al.</i> "A Pharmacokinetic Study of Sublingual Aerosolized Morphine in Healthy Volunteers", <i>Journal of Pharmacy and Pharmacology</i> 48(12) (1996).
	<a href="http://www.tomescps.com/hscdata/de/de0598.htm">http://www.tomescps.com/hscdata/de/de0598.htm</a> , pp. 1-289. Nifedipine
	<a href="http://www.tomescps.com/hcsdata/de/de0035.htm">http://www.tomescps.com/hcsdata/de/de0035.htm</a> , pp. 1-163. Nitroglycerin
	<a href="http://www.jpvet.aspetjournals.org/cgi/content/full/296/1/121#sec3">http://www.jpvet.aspetjournals.org/cgi/content/full/296/1/121#sec3</a> . Scopolamine
	Mahmood, "Clinical Pharmacokinetics and Pharmacodynamics of Selegiline", <i>Clinical Pharmacokinetics</i> 33(2), 91-102 (1997).
	Deneer <i>et al.</i> "Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects", <i>British Journal of Clinical Pharmacology</i> 45(5), 485-490 (1998).
	Russell <i>et al.</i> "Pharmacokinetics of a New Sublingual Formulation of Temazepam", <i>European Journal of Clinical Pharmacology</i> 35(4) (1988).

Examiner

Date Considered

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.